The Rheumatologist
COVID-19 News
You are here: Home / Articles / Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis

Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis

• By

Reference

  1. Novartis AG. News release: Novartis’ Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients. 2017 Nov 30.

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »